{
    "clinical_study": {
        "@rank": "23420", 
        "arm_group": [
            {
                "arm_group_label": "BIIB023", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be randomly assigned to receive intravenous (IV) infusions of BIIB023"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will be randomly assigned to receive intravenous (IV) infusions of placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine whether muscle atrophy induced by\n      immobilization of the lower limb can be attenuated by BIIB023 in healthy male volunteers.\n      The secondary objectives of this study in this study population are:\n\n        -  To determine whether muscle weakness induced by immobilization of the lower limb can be\n           attenuated by BIIB023\n\n        -  To assess the effect of BIIB023 on the recovery of muscle mass and strength after\n           immobilization\n\n        -  To assess the effect of BIIB023 on histological markers of muscle atrophy and\n           regeneration\n\n        -  To assess the effect of BIIB023 on muscle bioenergetics based on oxidative metabolism\n           recovery kinetics\n\n        -  To evaluate the safety and tolerability of BIIB023"
        }, 
        "brief_title": "A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Deemed healthy as determined by the Investigator based on medical history, 12-lead\n             electrocardiogram, vital signs, and clinical laboratory parameters at Screening, and\n             physical examination at Baseline\n\n          -  Body mass index (BMI) between 18.5 and 32 kg/m2, inclusive, at the time of Screening\n\n          -  Willing to abstain from using tobacco and tobacco-containing products during the\n             study\n\n          -  Willing to limit the intake of alcohol to no more than 2 units per day throughout the\n             study; exceptions are 48 hours prior to Screening, 48 hours prior to Day 1, and\n             during the in-clinic immobilization period when no alcohol will be permitted. One\n             unit of alcohol is defined as 12 fluid ounce (fl oz) of beer, 5 fl oz of wine, or 1.5\n             fl oz of liquor\n\n          -  Willing to maintain a regular diet for the duration of the study and a recreational\n             level of physical activity defined as participation in an exercise program or other\n             physical activity at a level of intensity that does not exceed the level prior to\n             study entry\n\n          -  Practice effective contraception during the study and be willing and able to continue\n             contraception for at least 6 months after the last dose of study treatment.\n\n        Key Exclusion Criteria:\n\n          -  History of or positive test result at Screening for human immunodeficiency virus\n             (HIV).\n\n          -  History or positive test result at Screening for hepatitis C virus (HCV) antibody or\n             hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or\n             hepatitis B core antibody [HBcAb]).\n\n          -  History of tuberculosis (TB) or a positive QuantiFERON\u00ae-TB Gold test. There must be\n             no other clinical evidence of TB on physical examination of the subject.\n\n          -  Use of tobacco or tobacco-containing products within 3 months prior to Screening\n\n          -  Known history of thrombophilia, hypercoagulopathy, or prior history of deep vein\n             thrombosis (DVT) or pulmonary embolism (PE)\n\n          -  History of physical activity consistent with endurance training or resistance\n             training within 6 months prior to Screening\n\n          -  Any back, leg, knee, or shoulder complaints that may interfere with the use of\n             crutches\n\n          -  Prolonged travel (more than 6 hours) within 2 weeks prior to randomization.\n\n        NOTE:  Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943513", 
            "org_study_id": "211HV103"
        }, 
        "intervention": [
            {
                "arm_group_label": "BIIB023", 
                "description": "Intravenous infusion", 
                "intervention_name": "BIIB023", 
                "intervention_type": "Biological", 
                "other_name": "(anti-TWEAK [TNF-related Weak Inducer of Apoptosis] monoclonal antibody)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo intravenous infusion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Muscle Disuse Atrophy", 
        "lastchanged_date": "March 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Evansville", 
                    "country": "United States", 
                    "state": "Indiana"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Intravenous BIIB023 (Anti-TWEAK) on Lower Limb Muscle Mass and Strength During and After Knee-Joint Immobilization in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percentage change in the magnitude of muscle atrophy", 
            "safety_issue": "No", 
            "time_frame": "between Day 14 and Day 42"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943513"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage change in the magnitude of muscle atrophy, measured by T1W-MRI analysis of the CSA of the triceps surae muscles of the immobilized limb", 
                "safety_issue": "No", 
                "time_frame": "between Day 14 and Day 42"
            }, 
            {
                "measure": "Percentage change in isometric knee-extension strength (torque), measured by dynamometry", 
                "safety_issue": "No", 
                "time_frame": "between Day 14 and Day 42"
            }, 
            {
                "measure": "Percentage change in isometric plantar-flexion strength (torque), measured by dynamometry", 
                "safety_issue": "No", 
                "time_frame": "between Day 14 and Day 42"
            }, 
            {
                "measure": "Percentage change in total CSA of Type I and II fibers, measured by histological analysis of muscle biopsy", 
                "safety_issue": "No", 
                "time_frame": "between Day 14, Day 21, and Day 42"
            }, 
            {
                "measure": "Change in density of satellite cells and other molecular markers of muscle regeneration, measured by histological analysis of muscle biopsy", 
                "safety_issue": "No", 
                "time_frame": "between Day 14, Day 21, and Day 42"
            }, 
            {
                "measure": "Change in the recovery of muscle oxidative metabolism, measured by near-infrared spectroscopy (NIRS) of the quadriceps femoris muscles", 
                "safety_issue": "No", 
                "time_frame": "between Day 14 and Day 42"
            }, 
            {
                "measure": "The number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 156"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}